Table 1.
Clinicopathological features related to MSI status
| MSS, n=201 (82%) | MSI, n=45 (18%) | P value | |
| Characteristics | |||
| Median age (range) | 68.1 (34–91) | 75.9 (52–95) | <0.001* |
| Gender, n (%) | |||
| Female | 57 (28.3) | 24 (53.3) | 0.001† |
| Male | 144 (71.6) | 21 (46.6) | |
| Location, n (%) | |||
| GEJ and cardia | 54 (26.8) | 5 (11.1) | 0.03† |
| Body and antrum | 141 (70.1) | 40 (88.8) | |
| Gastric pouch | 6 (2.9) | 0 | |
| Lauren histological classification, n (%) | |||
| Intestinal | 124 (61.6) | 30 (66.6) | 0.13† |
| Diffuse | 55 (27.3) | 7 (15.5) | |
| Mixed | 22 (10.9) | 8 (17.7) | |
| Tumour location-modified Lauren classification, n (%) | |||
| PND | 43 (21.3) | 4 (8.8) | 0.05† |
| D | 77 (38.3) | 15 (33.3) | |
| DND | 81 (40.3) | 26 (57.7) | |
| pTNM stage, n (%) | |||
| I | 35 (23) | 8 (20) | 0.40† |
| II | 44 (28.9) | 12 (30) | |
| III | 58 (38.1) | 19 (47.5) | |
| IV | 15 (9.8) | 1 (2.5) | |
| pN stage, n (%) | |||
| N0 | 62 (41.1) | 13 (33.3) | 0.06† |
| N1 | 23 (15.2) | 11 (28.2) | |
| N2 | 28 (18.5) | 9 (23.1) | |
| N3 | 38 (25.2) | 6 (15.4) | |
| Lymphovascular invasion, n (%) | |||
| Absent | 65 (43) | 18 (45) | 0.82† |
| Present | 86 (57) | 22 (55) | |
| EBER expression, n (%) | |||
| Positive | 10 (6) | 3 (7) | 0.74† |
| Negative | 158 (94) | 38 (93) | |
Significant p-values are shown in bold
*Wilcoxon test.
†2 test.
D, diffuse; DND, distal non-diffuse; EBER, Epstein-Barr virus-encoded small RNAs; GEJ, gastro-oesophageal junction; MSI, microsatellite instability; MSS, microsatellite stable; PND, proximal non-diffuse; pN, pathological N; pTNM, pathological TNM.